Advancing Alzheimer's Treatment Means Using The Best Biomarker(s) — But Which?
Clinical Leader,
By Frederick Huie, MD, SYNAPS Dx advisory council member, and Emmanuel C. Gorospe, MD, MPH, CPI, FACP, chief medical officer…
By Frederick Huie, MD, SYNAPS Dx advisory council member, and Emmanuel C. Gorospe, MD, MPH, CPI, FACP, chief medical officer…
Symptoms of dementia can be difficult to differentiate from typical age-related behavior changes and other common and…
It’s time to cut through the noise on coverage decisions and restricted access to new drugs for Alzheimer disease (AD)—lecanemab…
Alzheimer disease (AD) is the most common cause of dementia and represents the most frequently diagnosed neurodegenerative…